Videos & Visuals
In an interview with Pharmacy Times during the 2026 Cardiology Day of Education, Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS (AQ-Cardiology), CACP, a…
When a patient is diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM), the news lands hard. It's a rare, progressive cardiovascular disease in which…
By FACET FEATURING Mahwash Kassi, Ernesto Ruiz, Michael Middleton, Debby Rampisela, E Rene Rodriguez, Andrew Kontak, Haojie Wang, Nitasha Saraswat
A new three-year initiative from the American Heart Association (AHA) is seeking to improve how clinicians identify and manage cardiac amyloidosis. It was once…
OverviewCertain signs and symptoms can increase suspicion for transthyretin amyloid cardiomyopathy (ATTR-CM) even before clear cardiac involvement is present.…
In this episode, Sheila Arquette, President & CEO of NASP, speaks with Marina Carter, PharmD, BCACP, Ambulatory Clinical Pharmacy Specialist with Carilion…
Greg Foster, 4-time world champion and Olympic Silver medalist, discusses his journey to diagnosis. Learn more about his initial symptoms, multiple doctors visits,…
Kevin M. Alexander, MD, eagerly awaits the presentation of new amyloid dataat the 2026 ACC meeting in New Orleans and is especially interested in the subgroup…
Welcome back to another AJMC Payer Perspectives series. In this opening episode titled, ‘Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Clinical Burden and…
Long-term survival benefits were seen in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) using the drug acoramidis (Attruby) in new data presented at…